产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
猜你想搜
首页 制药产品大全 原料药 Resmetirom

Resmetirom

2026-07-24
920509-32-6
企业标准
药用级

产品详情

Resmetirom
消化系统用药原料
920509-32-6
企业标准
药用级
MASH/=NASH/=Rezdiffra/=Madrigal
是
中国,北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲
是

产品描述

Product Name: Resmetirom API

Chemical Name: 2-[3,5-Dichloro-4-[(4-hydroxy-3-isopropylphenoxy)phenyl]methyl]thiazole-4-carboxylic acid

Molecular Formula: C₂₁H₁₈Cl₂NO₄S

Molecular Weight: 451.34 g/mol

CAS Number: 913390-85-1

Therapeutic Category: Thyroid Hormone Receptor (THR)-β Selective Agonist

Indication: Resmetirom is an investigational drug primarily developed for the treatment of non-alcoholic steatohepatitis (NASH/MASH) and other metabolic disorders. It selectively activates the thyroid hormone receptor beta (THR-β), which plays a key role in regulating lipid metabolism, reducing liver fat, and improving liver function.

Mechanism of Action: Resmetirom is a liver-directed, selective thyroid hormone receptor beta (THR-β) agonist. By selectively activating THR-β, it enhances lipid metabolism, reduces hepatic fat accumulation, and improves markers of liver inflammation and fibrosis. Unlike non-selective thyroid hormone agonists, Resmetirom minimizes off-target effects on the heart and bones by sparing the THR-α receptor.

Dosage Form: Resmetirom is available as an active pharmaceutical ingredient (API) for formulation into oral dosage forms, such as tablets or capsules.

Pharmacokinetics:

  • Absorption: Resmetirom is well-absorbed following oral administration, with peak plasma concentrations achieved within a few hours.
  • Distribution: It exhibits a high degree of liver targeting, with minimal distribution to extrahepatic tissues.
  • Metabolism: Resmetirom is primarily metabolized in the liver via glucuronidation and oxidation pathways.
  • Excretion: The drug and its metabolites are predominantly excreted in the feces.

Storage Conditions: Resmetirom API should be stored in a cool, dry place, protected from light and moisture.

Stability: Resmetirom is stable under recommended storage conditions. It should be protected from extreme temperatures and humidity to maintain its stability and efficacy.

Regulatory Status: Resmetirom is currently under clinical development and has not yet received approval for commercial use. It is being evaluated in various clinical trials to assess its safety and efficacy in treating non-alcoholic steatohepatitis (NASH) and related metabolic conditions.

Packaging: Resmetirom API is supplied in sealed, light-resistant containers to ensure product integrity. The packaging is designed to protect the API from environmental factors that could compromise its quality.

Quality Standards: Resmetirom API is manufactured in compliance with current Good Manufacturing Practices (cGMP) and meets stringent quality control standards to ensure its purity, potency, and consistency.

Applications: Resmetirom API is intended for use in the development and production of pharmaceutical formulations aimed at treating non-alcoholic steatohepatitis (NASH) and other metabolic disorders. It is suitable for use in both clinical trials and commercial pharmaceutical manufacturing.

Note: This product is intended for research and development purposes only. It is not for human or veterinary use unless specified by regulatory authorities.

山东百诺医药股份有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

百诺创立于2000年,作为全球高端API供应商、MAH产品运营商、高品质医药健康产品供应商,我们持续致力于大健康领域,立足全球化视野,构建了创新药研发平台、仿制药研发平台、原料研发平台、生产制造平台(山东朗诺制药有限公司)、BE试验平台、上市后管理平台、MAH持证平台等医药研发生产完整产业链,我们秉承最高的合规标准和商业诚信,以ICH指导原则为指南,原料药及制剂产品已进入国际供应链。未来将以AI技术、绿色制造为引擎,深化“一带一路”医药合作,推动中国医药产品与服务惠及全球,成为国际健康产业的核心创新力量。 Biocom旗下子公司山东朗诺制药有限公司成立于2012年,是一家以提供高端API产品和制制剂CMO服务为核心业务的高新技术企业。公司建立了符合CGMP的质量管理体系,通过了国际环境管理体系(ISO14001)认证和国际职业健康与安全管理体系(ISO45001)认证,具备向全球供应高端API产品的研发、制造和全球注册能力。 朗诺制药依托300余人的高水平研发团队,目前已获得日本AFM许可,美国FDA DMF获批原料药10+个,欧盟获批原料药3个,韩国获批原料药3个,国内注册原料药50余个,制剂注册80余个,产品管线涵盖心脑血管系统类、消化系统类、抗肿瘤类、神经系统类等多个领域。
业务类型:
成立日期:
年营业额:
主营产品类别: